Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
Status:
Completed
Trial end date:
2001-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Bcl-2 antisense oligodeoxynucleotide G3139 may increase the
effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug.
PURPOSE: Phase I/II trial to study the effectiveness of bcl-2 antisense oligodeoxynucleotide
G3139 and paclitaxel in treating patients who have recurrent small cell lung cancer.